Swiss Medica's O24 Pain Relief Product Shows Improvement in Fibromyalgia

Swiss Medica has announced positive results of the randomized, double-blind, clinical trial comparing the company's O24 pain reliever against a placebo on patients suffering from fibromyalgia.

The four-to-six-week pilot study included 153 fibromyalgia subjects, of which 133 participants completed the study with 68 using a placebo. The other 65 used the O24 product.

Assessments of these participants were carried out at multiple community clinics in the Greater Toronto Area. "The group treated with O24 compared to placebo showed statistically significant improvement when measured on the Visual Analog Scale [VAS] for pain," said Gordon Ko, a director of the study.

Improvement was also statistically significant for VAS night pain, Jamar hand-grip strength, total number of fibromyalgia tender points and the average tender point pain threshold as measured by algometry. For participants who used O24, more than 90 percent of the patients reported mild to markedly better improvement on the seven-point Lanier rating scale. Nearly 54 percent reported moderately better or markedly better results using O24 instead of the placebo.

Roughly 80 percent of the placebo group reported no change in their condition, and 13 percent reported a worsening of their condition. Only 7 percent reported mild improvement from the placebo.